Informations générales (source: ClinicalTrials.gov)
Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience (FOR-HYPO)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
juin 2019
décembre 2020
29 juin 2024
Pediatric hypoparathyroidism is an orphan disease. Conventional management combines
native and active vitamin D, calcium supplementation and sometimes phosphate binders,
with the risk of long term hypercalciuria, nephrocalcinosis and further renal impairment.
The use of teriparatide has been reported in adults (daily or bi-daily subcutaneous
infusions) and in children (rather continuous subcutaneous infusion) as second-line
therapy.
The objective of this study is to obtain efficacy and safety data on the use of
teriparatide in children with hypoparathyroidism to improve our knowledge of their
management.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant - Bron - France | Justine BACCHETTA, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients with hypoparathyroidism
- Patients treated with teriparatide
- Patients followed in the reference center for calcium and phosphate metabolism
diseases of Lyon.
- For children under 18: patient and parent (s) / parent having been informed of the
study and having expressed their non-opposition
- Patients with hypoparathyroidism
- Patients treated with teriparatide
- Patients followed in the reference center for calcium and phosphate metabolism
diseases of Lyon.
- For children under 18: patient and parent (s) / parent having been informed of the
study and having expressed their non-opposition
- No social security support